Linsitinib (OSI-906)

For research use only. Not for use in humans.

目录号：S1091

CAS No. 867160-71-2

Linsitinib (OSI-906)是一种选择性IGF-1R抑制剂，在无细胞试验中IC50为35 nM；对InsR抑制作用适中，IC50为75 nM，对Abl，ALK，BTK，EGFR， FGFR1/2，PKA等没有抑制活性。Phase 3。

规格

价格

库存

购买数量

5mg	RMB 1393.48	现货
10mg	RMB 2226.24	现货
50mg	RMB 5899.91	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Linsitinib (OSI-906)发表文献115篇：

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2018, 560(7719):499-503

PubMed: 30051890 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):439-452

PubMed: 30205046 ( click the link to review the publication )

Nature, 2016, 24;539(7630):570-574.

PubMed: 27820945 ( click the link to review the publication )

Cancer Cell, 2015,

PubMed: 25670080 ( click the link to review the publication )

Nat Med, 2014, 20(9):1027-34

PubMed: 25173427 ( click the link to review the publication )

Nat Commun, 2020, 11(1):4607

PubMed: 32929081 ( click the link to review the publication )

J Invest Dermatol, 2020, 3 pii: S0022-202X(20)31407-X

PubMed: 32376279 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 13;5(1):53

PubMed: 32398667 ( click the link to review the publication )

FASEB J, 2020, 34(4):5363-5388

PubMed: 32067272 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(3):920-926

PubMed: 31871269 ( click the link to review the publication )

Front Endocrinol (Lausanne), 2020, 16;11:219

PubMed: 32373071 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

Oncol Rep, 2020, 44(4):1649-1661

PubMed: 32945502 ( click the link to review the publication )

Biol Pharm Bull, 2020, 10.1248/bpb.b20-00362

PubMed: 32863294 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):549-559

PubMed: 31941753 ( click the link to review the publication )

Acta Pharm Sin B, 2020, 10(1):186-194

PubMed: 31993315 ( click the link to review the publication )

Nat Commun, 2019, 10(1):518

PubMed: 30705270 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2244-2256

PubMed: 30833419 ( click the link to review the publication )
Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Aging Cell, 2019, 18(3):e12932

PubMed: 30884121 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32668

PubMed: 31490549 ( click the link to review the publication )

Cell Mol Life Sci, 2019, 76(6):1185-1199

PubMed: 30623207 ( click the link to review the publication )

Cancer Lett, 2019, 456:59-68

PubMed: 31042587 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

FASEB J, 2019, 33(10):11210-11222

PubMed: 31291762 ( click the link to review the publication )

Cells, 2019, 8(4)

PubMed: 30965609 ( click the link to review the publication )

J Gerontol A Biol Sci Med Sci, 2019, 74(9):1375-1385

PubMed: 30329021 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(17)

PubMed: 31480400 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

Mediators Inflamm, 2019, 2019:5497467

PubMed: 31467485 ( click the link to review the publication )

Endocr Connect, 2019, 8(6):680-690

PubMed: 31035254 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1777

PubMed: 29725014 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3440

PubMed: 30143629 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2546

PubMed: 29959327 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1580

PubMed: 30274984 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1574

PubMed: 30279230 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-0372

PubMed: 30397176 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(17):4282-4296

PubMed: 29716918 ( click the link to review the publication )

Genes Dev, 2018, 32(13-14):915-928

PubMed: 29945888 ( click the link to review the publication )

Biomaterials, 2018, 155:64-79

PubMed: 29169039 ( click the link to review the publication )

Cancer Res, 2018, 78(14):3995-4006

PubMed: 29669759 ( click the link to review the publication )
Mol Cancer, 2018,

PubMed: 29455661 ( click the link to review the publication )

Cancers (Basel), 2018, 10(9)

PubMed: 30227608 ( click the link to review the publication )

J Mol Cell Biol, 2018, 10(4):331-340

PubMed: 29190376 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2217-2225

PubMed: 30045926 ( click the link to review the publication )

Cell Oncol, 2018, 41(3):283-296

PubMed: 29470830 ( click the link to review the publication )

Endocrinology, 2018, 159(1):285-296

PubMed: 29029116 ( click the link to review the publication )

Front Endocrinol, 2018, 9:178

PubMed: 29731738 ( click the link to review the publication )

PLoS One, 2018, 13(2):e0191890

PubMed: 29389967 ( click the link to review the publication )

Oncotarget, 2018, 9(10):8810-8822

PubMed: 29507656 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29416603 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(11):2795-2805

PubMed: 27903677 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1842-1853

PubMed: 28209619 ( click the link to review the publication )

Theranostics, 2017, 7(4):974-986

PubMed: 28382169 ( click the link to review the publication )

Cancer Res, 2017, 77(15):4014-4025

PubMed: 28619711 ( click the link to review the publication )

Oncogene, 2017,

PubMed: 28534511 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(4):328-340

PubMed: 27987211 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):705-716

PubMed: 28138037 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):88-101

PubMed: 28062706 ( click the link to review the publication )

Mol Cancer Res, 2017,

PubMed: 28289161 ( click the link to review the publication )

Endocrinology, 2017,

PubMed: 29028997 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(11):895-903

PubMed: 28696156 ( click the link to review the publication )

Cancer Med, 2017, 6(6):1353-1361

PubMed: 28440057 ( click the link to review the publication )

Biochimie, 2017, 138:62-69

PubMed: 28438671 ( click the link to review the publication )
J Cell Biochem, 2017, 118(7):1774-1781

PubMed: 27987331 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0170083

PubMed: 28076448 ( click the link to review the publication )

Exp Lung Res, 2017, 43(1):29-37

PubMed: 28394654 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103465-103476

PubMed: 29262576 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28002807 ( click the link to review the publication )

Hepatology, 2017, 66(6):2002-2015

PubMed: 28653763 ( click the link to review the publication )

Mol Cancer Ther, 2016,

PubMed: 27196766 ( click the link to review the publication )

Endocr Relat Cancer, 2016, 23(6):481-93

PubMed: 27185872 ( click the link to review the publication )

Front Cell Dev Biol, 2016, 4:114

PubMed: 27800477 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(5):411-22

PubMed: 26785999 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2016, 55(6):779-791

PubMed: 27438786 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:6843-6855

PubMed: 27877053 ( click the link to review the publication )

Science, 2016, 352(6288):aad3018

PubMed: 27199435 ( click the link to review the publication )

Oncotarget, 2016, 7(35):56826-56841

PubMed: 27472395 ( click the link to review the publication )

Oncotarget, 2016, 7(19):27511-26

PubMed: 27050276 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(6):1373-82

PubMed: 25609059 ( click the link to review the publication )

Mol Cancer, 2015,

PubMed: 26041671 ( click the link to review the publication )

J Bone Miner Res, 2015, 30(11):1959-68

PubMed: 25990470 ( click the link to review the publication )

J Clin Endocrinol Metab, 2015, 100(3):1071-7

PubMed: ( click the link to review the publication )

J Clin Endocrinol Metab, 2015, 100(3):1071-7

PubMed: 25485727 ( click the link to review the publication )

Mol Cancer Res, 2015,

PubMed: 26263910 ( click the link to review the publication )

Mol Cell Biol, 2015, 35(17):2991-3004

PubMed: 26100015 ( click the link to review the publication )

Vascul Pharmacol, 2015, 10.1016/j.vph.2015.04.005

PubMed: 25921925 ( click the link to review the publication )
Med Oncol, 2015, 32(6):577

PubMed: 25956506 ( click the link to review the publication )

PLoS One, 2015, 10(1):e0116895

PubMed: 25603314 ( click the link to review the publication )

Biomarkers, 2015,

PubMed: 26329528 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26515601 ( click the link to review the publication )

Int J Clin Exp Med, 2015, 8(4):6563-7

PubMed: 26131286 ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )

Leukemia, 2014, 28(11):2197-205

PubMed: 24699302 ( click the link to review the publication )

Endocrinology, 2014, 155(6):2102-11

PubMed: 24712877 ( click the link to review the publication )

Pharm Res, 2014, 31(11):3060-72

PubMed: 24906597 ( click the link to review the publication )

Arch Biochem Biophys, 2014, 558C:42-50

PubMed: 24933099 ( click the link to review the publication )

J Cell Biochem, 2014, 115(12):2208-17

PubMed: 25147082 ( click the link to review the publication )

Biometals, 2014, 27(2):317-32

PubMed: 24535192 ( click the link to review the publication )

Blood, 2013, 122(9):1621-33

PubMed: 23863897 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Diabetes, 2013, 62(10):3448-58

PubMed: 23801577 ( click the link to review the publication )

BMC Cancer, 2013, 13:245

PubMed: 23688189 ( click the link to review the publication )

Cancer Cell Biology, 2013, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Cancer Res, 2012, 73(2):834-43

PubMed: 23172312 ( click the link to review the publication )

Cancer Res, 2011, 71(21):6773-84

PubMed: 21908557 ( click the link to review the publication )

产品安全说明书

IGF-1R抑制剂选择性比较

生物活性

产品描述

靶点

IGF-1R ^[1] (Cell-free assay)	Insulin Receptor ^[1] (Cell-free assay)	IRR ^[1] (Cell-free assay)
35 nM	75 nM	75 nM

体外研究

OSI-906 抑制IGF-IR自磷酸化和下游信号蛋白AKT, ERK1/2和S6激酶的激活，IC50为0.028到 0.13 μM。OSI-906通过与C-螺旋相互作用而使靶点蛋白形成中间结构形态。OSI-906作用于肝脏微粒体，具有良好的代谢稳定性。OSI-906浓度为1μM时，完全抑制IR 和IGF-IR磷酸化。OSI-906抑制一些肿瘤细胞系增殖，包括非小细胞肺癌和结肠直肠癌(CRC)肿瘤细胞系，EC50为0.021到 0.810 μM。^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
A4-Fuk	NUfnZWF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHKTWM2OD1yLkCyPFA3KM7:TR?=	NGO0OppUSU6JRWK=
KS-1	M4HSVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEO2fWRKSzVyPUCuNFM5OzVizszN	NF3HSlZUSU6JRWK=
TE-11	M4r0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzGTWM2OD1yLkC3PFIzKM7:TR?=	M3Lrd3NCVkeHUh?=
EW-1	NVjxcFBTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLjTWM2OD1yLkC4OVg2KM7:TR?=	MnPsV2FPT0WU
HMV-II	M2O2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWSzO5lHUUN3ME2wMlA5QDR4IN88US=>	M2jQS3NCVkeHUh?=
COLO-205	NWDQbG5FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnSWGF3UUN3ME2wMlExPDV2IN88US=>	NIrBWWRUSU6JRWK=
ES1	MmHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jtWGlEPTB;MD6xNFY6PiEQvF2=	NHPtdIRUSU6JRWK=
GDM-1	M3f6dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTrWGxKSzVyPUCuNVM3PzJizszN	NGfYNndUSU6JRWK=
ML-2	NETjfYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTwTXVKSzVyPUCuNVU5QTZizszN	MmTnV2FPT0WU
Saos-2	M4TYNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDzTWM2OD1yLkG2OVI3KM7:TR?=	NVfxNXk2W0GQR1XS
NCI-H1355	NV3hT2U{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfRNlRRUUN3ME2wMlE5OTN3IN88US=>	MmjhV2FPT0WU
G-401	M4jsWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHRTWM2OD1yLkG4NlMh\|ryP	Mly0V2FPT0WU
EW-16	NFXqUG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXORXVKSzVyPUCuNVg4PzdizszN	NH7FenhUSU6JRWK=
EW-7	M2jFe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;NSWlEPTB;MD6xPFg5OSEQvF2=	M{X0dHNCVkeHUh?=
NCI-H727	NXq5O2p1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTBwMUm3PVQh\|ryP	MXLTRW5ITVJ?
LCLC-97TM1	M{P4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HESmlEPTB;MD6yNFk2PSEQvF2=	M1LvZ3NCVkeHUh?=
NCI-H650	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofqTWM2OD1yLkKxN\|g1KM7:TR?=	NH7RTXRUSU6JRWK=
NCI-H2122	MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnqxTWM2OD1yLkKzNlk6KM7:TR?=	M{LTWHNCVkeHUh?=
SK-N-DZ	M{LsTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLBd\|ZCUUN3ME2wMlI{Pjl6IN88US=>	NYni[IdXW0GQR1XS
HT-29	NUTS[5p6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LlXGlEPTB;MD6yOFI1QCEQvF2=	NYK3WWFjW0GQR1XS
LB771-HNC	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\1[G5KSzVyPUCuNlU6OTVizszN	NY[1[JlWW0GQR1XS
HT-144	NEPORmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\EU\|g{UUN3ME2wMlI3OTlzIN88US=>	NIrZUItUSU6JRWK=
LAN-6	M4fHVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTBwMk[zOFgh\|ryP	MVjTRW5ITVJ?
EW-18	NH7WT21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;tWZlKSzVyPUCuNlcxODFizszN	MVfTRW5ITVJ?
LS-1034	M4ftUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3iwSmlEPTB;MD6yO\|E{OiEQvF2=	NHryTGdUSU6JRWK=
EW-11	NEGyTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPFNI9KSzVyPUCuNlg1OzJizszN	M1P3OXNCVkeHUh?=
SNU-C1	MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPRTWM2OD1yLkK5N\|E{KM7:TR?=	NIrCcGpUSU6JRWK=
RS4-11	MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TCVWlEPTB;MD6zN\|c2QCEQvF2=	NX3VN3ozW0GQR1XS
ES4	MnLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\SeGlEPTB;MD60NVA{QCEQvF2=	MVnTRW5ITVJ?
COLO-320-HSR	NUnNVXZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfyZ2pKSzVyPUCuOFE{PjhizszN	M{XWfHNCVkeHUh?=
NB10	NYnJOIZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXmZ2ZKSzVyPUCuOFU1OzdizszN	NV;lWYM1W0GQR1XS
BFTC-905	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELSd49KSzVyPUCuOFY4PThizszN	MojHV2FPT0WU
A375	NEfpTYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TzbWlEPTB;MD60O\|YyPyEQvF2=	M3;RcnNCVkeHUh?=
SJRH30	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PEb2lEPTB;MD61NFgzOiEQvF2=	M2TNOnNCVkeHUh?=
NOS-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjFTWM2OD1yLkWyNlY4KM7:TR?=	NF\qU4NUSU6JRWK=
SIG-M5	NGTabolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPndFE2UUN3ME2wMlU{PTV5IN88US=>	M2LwVHNCVkeHUh?=
DOK	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfUWXBKSzVyPUCuOVU3KM7:TR?=	MmDZV2FPT0WU
NB69	M4HlOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4D5[WlEPTB;MD61PFI2PyEQvF2=	MUPTRW5ITVJ?
SK-NEP-1	MnfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4X6[WlEPTB;MD62NFI{PiEQvF2=	NGjwTI9USU6JRWK=
SK-MM-2	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXyTWM2OD1yLk[1OFkyKM7:TR?=	M1[5THNCVkeHUh?=
NCI-H358	MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTBwNkewPFIh\|ryP	MXPTRW5ITVJ?
RH-1	NV\NO5RrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTBwN{S4OVkh\|ryP	MoLQV2FPT0WU
NH-12	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXiOYlKSzVyPUCuO\|YxPDZizszN	MoXrV2FPT0WU
TE-12	NIXle\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUX6eoo2UUN3ME2wMlc3PDh4IN88US=>	NYnFXXlNW0GQR1XS
COLO-668	NUW0N3EyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XLTWlEPTB;MD64OFY3PiEQvF2=	NXvE[lNCW0GQR1XS
PANC-08-13	NFSzOFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTFTWM2OD1yLki2N\|c4KM7:TR?=	NWj6V5p{W0GQR1XS
HCC2998	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzCWWtKSzVyPUCuPFgzPjNizszN	NXzFPHlRW0GQR1XS
ABC-1	M1XIZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTBwOUCzOVIh\|ryP	M4XVdnNCVkeHUh?=
ES6	MkXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3ywcGlEPTB;MD65NVA3PiEQvF2=	M{LqNHNCVkeHUh?=
SNU-387	NGjucWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M365PGlEPTB;MD65PVM6OyEQvF2=	NFvSd4xUSU6JRWK=
CMK	NXjMOoVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTBwOUm5Nlkh\|ryP	M{T2RXNCVkeHUh?=
SJSA-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVP1OmhNUUN3ME2xMlA{PjV\|IN88US=>	NV;ybZZIW0GQR1XS
SIMA	NICw[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPxTWM2OD1zLkC2PFI2KM7:TR?=	NIPTcGFUSU6JRWK=
ES3	NWnqT3duT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\6TWM2OD1zLkGyNlk4KM7:TR?=	MknUV2FPT0WU
IGROV-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTFwMUW0OFQh\|ryP	NX3Me2hCW0GQR1XS
MEL-JUSO	NYn5fYdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfsZldoUUN3ME2xMlE2PzV7IN88US=>	NUe2OoF3W0GQR1XS
T84	NEnIWJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDz[mRHUUN3ME2xMlIxQTF2IN88US=>	NGi1PJFUSU6JRWK=
CAL-85-1	NYHEbWFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHObJBjUUN3ME2xMlI{OTN6IN88US=>	M4jObnNCVkeHUh?=
RD	NIHHN\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTFwMk[0OVUh\|ryP	MkPtV2FPT0WU
TE-8	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIS2[lhKSzVyPUGuN\|E1PjJizszN	MoLIV2FPT0WU
L-363	NYDVNmdET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHz4V3RKSzVyPUGuN\|QzODhizszN	NVrucFZMW0GQR1XS
EKVX	NWHYO\|ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULlXVNVUUN3ME2xMlM1PTZ6IN88US=>	MmKwV2FPT0WU
SK-MEL-3	NV;4VXc1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfGNHdZUUN3ME2xMlQ5PTV4IN88US=>	NHfzfGlUSU6JRWK=
TGBC24TKB	Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2rWcGlEPTB;MT61NFE6OyEQvF2=	NFfoSJdUSU6JRWK=
NCI-H1770	NVvwU5JHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LRPWlEPTB;MT61NVEyOyEQvF2=	MmHIV2FPT0WU
HuH-7	NIrK[I1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TOS2lEPTB;MT62NFA6QCEQvF2=	NFrFZlNUSU6JRWK=
HL-60	M1;zfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4j0cWlEPTB;MT62OlkzQCEQvF2=	M4Pmb3NCVkeHUh?=
TE-1	NGTxeINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnq[G8xUUN3ME2xMlcxQTR3IN88US=>	M1zGSnNCVkeHUh?=
LC-2-ad	NUDObVNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\jO29jUUN3ME2xMlc{QDh5IN88US=>	MWjTRW5ITVJ?
LB647-SCLC	M4nVO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTFwN{[1PFMh\|ryP	NY\Md4VlW0GQR1XS
NCI-H2171	NH7iVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3H6PWlEPTB;MT63O\|cyPiEQvF2=	NGi4TYtUSU6JRWK=
SK-PN-DW	M2X1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2Dq[WlEPTB;MT65NVI6QCEQvF2=	M3S5RXNCVkeHUh?=
MC-IXC	NU\hdY5HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYD5ZXVDUUN3ME2xMlk5QThizszN	M1\Y[XNCVkeHUh?=
LS-513	Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTJwMEWzNFUh\|ryP	NEnuXIVUSU6JRWK=
EW-3	NIj0XnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DFc2lEPTB;Mj6wPVg1PCEQvF2=	MlrwV2FPT0WU
OPM-2	NX:4VHh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PEe2lEPTB;Mj6xNFIh\|ryP	M4DlRXNCVkeHUh?=
LP-1	NXXv[pVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTJwMkW4NFch\|ryP	NWfLclBiW0GQR1XS
LU-134-A	NYixO49PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\pTWM2OD1{LkK3O{DPxE1?	NEDMbZBUSU6JRWK=
CP66-MEL	NF;LRZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknaTWM2OD1{LkK5NFE1KM7:TR?=	Mk\UV2FPT0WU
HCC1143	MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7iTZJKSzVyPUKuOFU{PjhizszN	M2XiVHNCVkeHUh?=
LOXIMVI	M2\OR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XTNGlEPTB;Mj62NFIyKM7:TR?=	M4LJfXNCVkeHUh?=
TE-10	M2n4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnFTWM2OD1{LkewPFM5KM7:TR?=	M32wd3NCVkeHUh?=
NCI-H1882	M2eyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWK0bIZJUUN3ME2yMlc2OjJ5IN88US=>	NELBSGdUSU6JRWK=
CHP-126	MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTJwN{[zNVch\|ryP	NFLNNYVUSU6JRWK=
NCI-H1623	MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDTdpZKUUN3ME2yMlkzODJ2IN88US=>	M2PBfXNCVkeHUh?=
GB-1	NGLocpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13RNGlEPTB;Mj65N\|QxPCEQvF2=	NWDJRYlyW0GQR1XS
RCC10RGB	NFrCRlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7GfY1rUUN3ME2yMlk2OjhzIN88US=>	MlvXV2FPT0WU
NCI-H2141	M2iwNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHO[W9KSzVyPUKuPVY5QTZizszN	NHjneYVUSU6JRWK=
GI-ME-N	M3W2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV73SJVJUUN3ME2zMlAxPTZ3IN88US=>	MV\TRW5ITVJ?
NCI-H526	M3\TeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\1TWM2OD1\|LkC0NFg2KM7:TR?=	NGm3dHRUSU6JRWK=
NCI-H747	NI\4cmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTHTWM2OD1\|LkC0PVkzKM7:TR?=	M3TYb3NCVkeHUh?=
SNU-423	M{nXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPMTWM2OD1\|LkKwN\|E{KM7:TR?=	MX7TRW5ITVJ?
A427	NIHVNY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XobmlEPTB;Mz6yOVY6QSEQvF2=	Mlm5V2FPT0WU
CAL-12T	NInm[5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVexUnJ6UUN3ME2zMlQxPzF\|IN88US=>	M1zRUnNCVkeHUh?=
LU-99A	M{WxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH32Z4xKSzVyPUOuOFcyODVizszN	MYDTRW5ITVJ?
MS-1	NEPBOnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTuTWM2OD1\|LkWzOFI6KM7:TR?=	MmLIV2FPT0WU
SK-LU-1	M2fLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDCWGEzUUN3ME2zMlc3Ojl3IN88US=>	NHzMfnFUSU6JRWK=
SW837	NHe4[ZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFO2RWpKSzVyPUOuO\|Y{OzNizszN	M2XNNHNCVkeHUh?=
ES8	NYHDUZF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTNwOEO4O\|ch\|ryP	NV31UZA2W0GQR1XS
MZ2-MEL	M{DUXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33wcGlEPTB;Mz65NlA5PiEQvF2=	MXHTRW5ITVJ?
TGW	NXr0O4F[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFi5UGJKSzVyPUSuNFE{OTFizszN	M1O5S3NCVkeHUh?=
GP5d	M3vtemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUT4PJpWUUN3ME20MlA2OzZ{IN88US=>	M1\jd3NCVkeHUh?=
BB49-HNC	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTRwMUWyNVMh\|ryP	M2G4T3NCVkeHUh?=
NB13	NYDtfZBHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH6xbJlKSzVyPUSuNlY5QDdizszN	MkTvV2FPT0WU
NTERA-S-cl-D1	NYXHfHhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTRwMki2NVUh\|ryP	M1nucHNCVkeHUh?=
NCI-H1648	M1HOVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fYd2lEPTB;ND6yPVgyQSEQvF2=	NWLvPFlPW0GQR1XS
LCLC-103H	NEHrV49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTOdYRbUUN3ME20MlMzOTl3IN88US=>	M1q4cHNCVkeHUh?=
LS-411N	NV[wWINXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHWVJBMUUN3ME20MlQ1QDh3IN88US=>	MkDFV2FPT0WU
NCI-H1092	NX7HO4RZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXOUZBKSzVyPUSuOFU3QDdizszN	NVTXXIdWW0GQR1XS
PANC-10-05	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrHc2JKSzVyPUSuOlk5PCEQvF2=	NXOzbmRzW0GQR1XS
DK-MG	NIq5fHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXhTWM2OD12LkiwPVM{KM7:TR?=	M4LERXNCVkeHUh?=
OVCAR-5	MkXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIq4SFNKSzVyPUSuPFEzOjZizszN	MYrTRW5ITVJ?
CAL-39	M{XkXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLoTWM2OD12Lki3Olch\|ryP	NI\zOJBUSU6JRWK=
TE-441-T	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTRwOUC1N\|ch\|ryP	MV\TRW5ITVJ?
MOLT-16	NHf1c29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37ZfmlEPTB;ND65OVI2OyEQvF2=	NHvFbHlUSU6JRWK=
MCF7	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\oOFltUUN3ME21MlE1PTF5IN88US=>	M1jiXHNCVkeHUh?=
CAPAN-1	NIPtRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLiTWM2OD13LkK1O\|A4KM7:TR?=	MniwV2FPT0WU
PSN1	MlnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTVwMkeyN\|Uh\|ryP	MmHHV2FPT0WU
NCI-H292	NFz0VXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17tZmlEPTB;NT6zNFA1PCEQvF2=	MoTqV2FPT0WU
CPC-N	NEjkbG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jDTWlEPTB;NT6zPVQyQSEQvF2=	MnfRV2FPT0WU
DoTc2-4510	M1LUXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nRWGlEPTB;NT60OVM4OSEQvF2=	Mny0V2FPT0WU
LB1047-RCC	NFf4SmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTa[YhnUUN3ME21MlU2QTN\|IN88US=>	NFu0TmNUSU6JRWK=
MHH-ES-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\mTWM2OD13LkW5PVA4KM7:TR?=	MlHOV2FPT0WU
NMC-G1	NUDEd45LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnPO3JKSzVyPUWuO\|AzOjdizszN	MoiyV2FPT0WU
SW1710	MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTVwN{S3OVEh\|ryP	NEnISIpUSU6JRWK=
YAPC	M4rTeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTVwN{[yNFEh\|ryP	NViyNHRkW0GQR1XS
22RV1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHOfVVIUUN3ME21MlgxODF7IN88US=>	M{fhU3NCVkeHUh?=
COLO-679	NEeybWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLs[WlXUUN3ME21Mlg5QTR6IN88US=>	MWfTRW5ITVJ?
TCCSUP	Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTVwOUOyOVkh\|ryP	M2S4SnNCVkeHUh?=
C2BBe1	M1n6dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TI[WlEPTB;NT65N\|k4KM7:TR?=	NFP1bIRUSU6JRWK=
TE-15	NH;kS3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPMO4hKSzVyPU[uNFY3ODVizszN	M4DicnNCVkeHUh?=
SCLC-21H	M3rzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTZwMUC4OFMh\|ryP	NVTKVHRUW0GQR1XS
EoL-1-cell	NGD6[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTuPVVnUUN3ME22MlE3PTZ\|IN88US=>	NHf1bYFUSU6JRWK=
NKM-1	M1XyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jieGlEPTB;Nj6xOlcyKM7:TR?=	NWnjO\|RoW0GQR1XS
NCI-H1304	MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEK4WFRKSzVyPU[uNlc1OjhizszN	NI\OOGtUSU6JRWK=
NB6	M1LCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTZwMkm2NlIh\|ryP	MUPTRW5ITVJ?
NALM-6	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnrGTWM2OD14LkOzNlMh\|ryP	NEDSSW5USU6JRWK=
NCI-H522	M2\JN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHNeGpKSzVyPU[uN\|M{ODZizszN	NFTkfG5USU6JRWK=
MV-4-11	MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTZwM{ewO\|kh\|ryP	NIG5PFVUSU6JRWK=
LB2241-RCC	M2Xzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1j1d2lEPTB;Nj6zPFY3PyEQvF2=	MW\TRW5ITVJ?
NCI-H1417	MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPJXINsUUN3ME22MlQxQDR5IN88US=>	M3HlbXNCVkeHUh?=
HT-1197	NWnDOmhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrzSXRKSzVyPU[uOVcyOjJizszN	M4OyUHNCVkeHUh?=
P30-OHK	M{LUZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTUcnFpUUN3ME22MlYzPzdizszN	NEC0PFdUSU6JRWK=
ALL-PO	M1mwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTZwN{G5NVYh\|ryP	NUjaSVlSW0GQR1XS
OVCAR-4	NES3TW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYK3XW9JUUN3ME22Mlc2PDB3IN88US=>	NEG1RnhUSU6JRWK=
HCC2157	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nnbmlEPTB;Nj63O\|Q4PSEQvF2=	M2\sdnNCVkeHUh?=
NCI-H838	NFH5dY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTZwOU[0PUDPxE1?	NXqxepI{W0GQR1XS
NCI-H1299	MlLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvCO\|VrUUN3ME22Mlk4ODlizszN	NV[zcYRuW0GQR1XS
SW954	NUiyblJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTdwMkCwOlgh\|ryP	NIr2TmdUSU6JRWK=
NCI-H441	MoLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnP0TWM2OD15LkO0NFY2KM7:TR?=	M1PudnNCVkeHUh?=
SK-MEL-2	NIX2WFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LoeGlEPTB;Nz60PFM4OyEQvF2=	NH;5[o9USU6JRWK=
KARPAS-45	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTdwNkW5Nlkh\|ryP	MYDTRW5ITVJ?
CAL-54	MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zremlEPTB;Nz64Nlk4PyEQvF2=	Mm\nV2FPT0WU
KYSE-180	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPNN2pKSzVyPUeuPFg6PDFizszN	NFPITYdUSU6JRWK=
NCI-H187	NGrpOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfnTWM2OD15Lkm1PVQ4KM7:TR?=	NHHMWGJUSU6JRWK=
RT-112	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jzb2lEPTB;OD6wPVY4PyEQvF2=	MmnXV2FPT0WU
NCI-H1437	NXfJUJQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTQTWM2OD16LkC5O\|k2KM7:TR?=	MYnTRW5ITVJ?
SNU-449	MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRThwMkiyO\|Ih\|ryP	NVTLd3JmW0GQR1XS
HCC1187	NYrFdYp4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUWyO\|FbUUN3ME24MlI6OzlzIN88US=>	MmXlV2FPT0WU
NCI-H2030	M1jxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPWd5RKSzVyPUiuN\|c4OTRizszN	NE[4WGJUSU6JRWK=
HuO-3N1	NV[3bGVOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTGTWM2OD16LkO3PFQ1KM7:TR?=	MlzaV2FPT0WU
COLO-792	NW[0R\|Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3UfpdKSzVyPUiuOFE2OjdizszN	NWLXNVVoW0GQR1XS
MIA-PaCa-2	MlPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPUTWM2OD16Lki1OVA5KM7:TR?=	M2TUS3NCVkeHUh?=
SK-N-FI	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTlwMESyOUDPxE1?	M{jCcXNCVkeHUh?=
MMAC-SF	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTlwMEm3OVEh\|ryP	NInYTlZUSU6JRWK=
NCI-H28	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HGWGlEPTB;OT6xNFQ3QSEQvF2=	MojwV2FPT0WU
ETK-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn33TWM2OD17LkK5PVc1KM7:TR?=	MkfmV2FPT0WU
NCI-H1993	M1\PNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;jTWM2OD17LkS0NlYyKM7:TR?=	Mk\YV2FPT0WU
no-11	NXTvW\|RQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfVRYN6UUN3ME25MlQ4OTJizszN	NVvXSJE1W0GQR1XS
ChaGo-K-1	MlfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEP5WYhKSzVyPUmuOVE2QDNizszN	MXPTRW5ITVJ?
NCCIT	NIC0OIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjMO4lKSzVyPUmuOVMyPjlizszN	NGrIVohUSU6JRWK=
SAS	NYTIeoVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTFyLkK0PEDPxE1?	M1viWHNCVkeHUh?=
A673	MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrY[\|d4UUN3ME2xNE4{PzB2IN88US=>	M{TJWHNCVkeHUh?=
NCI-H1522	NY\jZ3VKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTMflBKSzVyPUGwMlM4ODdizszN	MoLlV2FPT0WU
NCI-H810	NYfiNm9QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjyTWM2OD1zMD6zPVA4KM7:TR?=	MnO5V2FPT0WU
IST-MES1	NY\INIlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nSZWlEPTB;MUCuOFU3PCEQvF2=	MXHTRW5ITVJ?
GR-ST	NYTPe\|k5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjyXXdwUUN3ME2xNE42ODJ2IN88US=>	M1P2XnNCVkeHUh?=
SUP-T1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2OxNGlEPTB;MUCuO\|MyPyEQvF2=	MlWxV2FPT0WU
NB5	MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYf5UXpkUUN3ME2xNE46ODJ{IN88US=>	NVq5cFlwW0GQR1XS
MZ1-PC	NF3VXY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7PV\|VKSzVyPUGwMlk2PzFizszN	M3nEcnNCVkeHUh?=
SK-CO-1	NET1PINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;6WmlEPTB;MUCuPVk{OSEQvF2=	M2DQbHNCVkeHUh?=
Capan-2	MkTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\WS2lEPTB;MUGuN\|E6QCEQvF2=	NWfaSZJrW0GQR1XS
697	MoSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTFzLk[3OVch\|ryP	NG\VfHlUSU6JRWK=
REH	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvnTWM2OD1zMT63OFUyKM7:TR?=	MoDvV2FPT0WU
GI-1	NWe2eFlqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXL3cGlxUUN3ME2xNU45PjF3IN88US=>	Mn;mV2FPT0WU
BB65-RCC	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDUZXJtUUN3ME2xNk4xQTF4IN88US=>	NGHlNWZUSU6JRWK=
NCI-H1651	NHrYV\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTF{LkK0O\|gh\|ryP	MlzYV2FPT0WU
NCI-H1618	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX:1fGdtUUN3ME2xNk4{QTd4IN88US=>	MXTTRW5ITVJ?
NCI-H2081	NFHlfXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTIU45KSzVyPUGyMlYyPDFizszN	MWjTRW5ITVJ?
GCIY	NF7iWJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\1PHFtUUN3ME2xNk44OjF\|IN88US=>	M{nUO3NCVkeHUh?=
NY	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXwTWM2OD1zMz6wOlQ{KM7:TR?=	MWTTRW5ITVJ?
PANC-03-27	NEC1UWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTF\|LkC4NFch\|ryP	MX3TRW5ITVJ?
BHY	NFLlN3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLzdWJMUUN3ME2xN{4zOTJzIN88US=>	Mn:4V2FPT0WU
SK-OV-3	M3zF[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3kTWM2OD1zMz6zO\|Y{KM7:TR?=	NYn6V2xPW0GQR1XS
5637	M4fKN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPyPJRKSzVyPUGzMlc4PTlizszN	NXz0dHpDW0GQR1XS
LC-1F	M3yzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljYTWM2OD1zND6wN\|U3KM7:TR?=	NX;NR3hkW0GQR1XS
SNB75	M3;zUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHTTWM2OD1zND6wN\|g{KM7:TR?=	NH:zO3hUSU6JRWK=
CHP-212	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LVeGlEPTB;MUSuNFQ3PCEQvF2=	M4XqcnNCVkeHUh?=
HT-1376	NHP5RmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\ud2lEPTB;MUSuNVEzPiEQvF2=	M1vVXHNCVkeHUh?=
MONO-MAC-6	NIi0dpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTF2LkG1NFIh\|ryP	NVzObo1JW0GQR1XS
CA46	MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjlOJhQUUN3ME2xOE4yQDJ5IN88US=>	NVL6[XRyW0GQR1XS
SCC-15	NWn4[HUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLaTWM2OD1zND61OVg{KM7:TR?=	NV[yWI03W0GQR1XS
ATN-1	NILL[odIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrWfHBKSzVyPUG0MlY3OjdizszN	MlrzV2FPT0WU
NCI-H2405	NVLhS45LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XBfmlEPTB;MUSuPFE2PyEQvF2=	NGHKeINUSU6JRWK=
NCI-H716	M3zzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33vcWlEPTB;MUSuPFQ6OyEQvF2=	MljIV2FPT0WU
SW620	NVL1fWMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3y5e2lEPTB;MUSuPVAyPCEQvF2=	M4ntOnNCVkeHUh?=
NCI-H226	MmX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\HVmlEPTB;MUSuPVA5PSEQvF2=	M33GT3NCVkeHUh?=
SW962	M4XlXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEC1[4JKSzVyPUG0Mlk1OzJizszN	MkfHV2FPT0WU
KYSE-150	NIjlfIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF6xV2JKSzVyPUG0Mlk2PSEQvF2=	NIK5Z\|BUSU6JRWK=
OCUB-M	NYXnVoNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3zTIRVUUN3ME2xOE46QDh\|IN88US=>	MX\TRW5ITVJ?
ES7	Mm\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTF3LkC5PFQh\|ryP	MmLwV2FPT0WU
SW1463	MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnYXm46UUN3ME2xOU41OjJ\|IN88US=>	MX7TRW5ITVJ?
CAKI-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LFfmlEPTB;MUWuOVM1PiEQvF2=	NEXySIhUSU6JRWK=
MKN28	MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTF3LkW0O\|kh\|ryP	MoXuV2FPT0WU
SW13	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHQXVhKSzVyPUG1MlYyQCEQvF2=	M4rtTXNCVkeHUh?=
A3-KAW	Mmj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTF3Lkm2PVch\|ryP	NX7HdWVJW0GQR1XS
LU-65	M3\HZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTF3Lkm3Olgh\|ryP	MX;TRW5ITVJ?
Calu-1	NGLrcJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvqe5lZUUN3ME2xOk4xOzZ6IN88US=>	NH\aVFdUSU6JRWK=
ST486	MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mle1TWM2OD1zNj6wOFMyKM7:TR?=	NGixbY5USU6JRWK=
BB30-HNC	MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmr1TWM2OD1zNj6xNlQ3KM7:TR?=	MX3TRW5ITVJ?
EGI-1	M{LFcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHUTWM2OD1zNj60OFYh\|ryP	M{G2W3NCVkeHUh?=
SH-4	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTF4LkS3N\|Eh\|ryP	MWHTRW5ITVJ?
MN-60	M{LF[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTF5LkKyPVch\|ryP	M3jSVnNCVkeHUh?=
MPP-89	MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofjTWM2OD1zNz6yOFU6KM7:TR?=	NVO0WVBjW0GQR1XS
A2780	NGD5fJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfsTWM2OD1zNz60NVM6KM7:TR?=	NHvFcW5USU6JRWK=
Daoy	NI\KRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Hkc2lEPTB;MUeuOFY6PSEQvF2=	Mn\lV2FPT0WU
NCI-H2126	M{XyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nDN2lEPTB;MUeuOFc4OSEQvF2=	M2jFW3NCVkeHUh?=
NCI-H1563	NUK3N5NQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkOyTWM2OD1zNz60PVE4KM7:TR?=	M1jQOHNCVkeHUh?=
8-MG-BA	M3z0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTF5Lk[2OFgh\|ryP	MXHTRW5ITVJ?
786-0	NGTEfFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjPNVRKSzVyPUG3Mlg{PTNizszN	MojGV2FPT0WU
AM-38	M1rKbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LvZWlEPTB;MUeuPVMxPiEQvF2=	M3XzS3NCVkeHUh?=
COLO-824	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFK0R5JKSzVyPUG4MlQ1OzZizszN	NXvzTHVXW0GQR1XS
SK-MEL-30	M3K1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHy3V5lKSzVyPUG4MlUxQDJizszN	NF3xPGdUSU6JRWK=
CESS	MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlf5TWM2OD1zOD63OlA6KM7:TR?=	MlizV2FPT0WU
BL-70	NF3NN\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPITWM2OD1zOD64NVU3KM7:TR?=	MVnTRW5ITVJ?
NCI-H2170	MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTF6LkmxO\|kh\|ryP	M2[3UXNCVkeHUh?=
HT-3	MnzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH36bnRKSzVyPUG4Mlk5OyEQvF2=	NXvKOVZrW0GQR1XS
BOKU	NGjNcpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDkTWM2OD1zOT6wN\|gyKM7:TR?=	M4jPcnNCVkeHUh?=
HPAF-II	M1jROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3YTWM2OD1zOT6zNFE2KM7:TR?=	M17kU3NCVkeHUh?=
KGN	MlHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrMS5NKSzVyPUG5MlQ4PjVizszN	MoSwV2FPT0WU
MC-CAR	M1XKT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTF7Lk[zNVMh\|ryP	M1fLUXNCVkeHUh?=
BHT-101	M4jLemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{CxOGlEPTB;MUmuO\|c4KM7:TR?=	M2WxSXNCVkeHUh?=
SW1783	MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrHTWM2OD1zOT63PFA3KM7:TR?=	Mki2V2FPT0WU
KP-N-YN	NFvkd2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfaN\|lKSzVyPUKwMlAzPjJizszN	NHLGXGNUSU6JRWK=
LU-165	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTkTWM2OD1{MD61OVcyKM7:TR?=	NWXHTIR3W0GQR1XS
GOTO	Mlu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTJyLk[0OVEh\|ryP	NHLWUnVUSU6JRWK=
EFM-19	NV34XpltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDxOod6UUN3ME2yNU4xPzF4IN88US=>	MU\TRW5ITVJ?
CTV-1	MoHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LsWmlEPTB;MkGuNVA2PCEQvF2=	MYnTRW5ITVJ?
HEL	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1G5cmlEPTB;MkGuOFIyPiEQvF2=	M2Wyd3NCVkeHUh?=
SNU-C2B	NUG1NnpqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2f0cWlEPTB;MkGuOFI3KM7:TR?=	MlnQV2FPT0WU
ECC4	NUW1T2ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjaTWM2OD1{MT63NFch\|ryP	Ml7yV2FPT0WU
NEC8	MlLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfhTWM2OD1{MT64N\|Y5KM7:TR?=	NGHhXW1USU6JRWK=
KMOE-2	Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTJzLki5NlEh\|ryP	NXHiRnp4W0GQR1XS
NCI-H524	M1HLdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTJ{LkC4NFgh\|ryP	NIrnfpZUSU6JRWK=
WSU-NHL	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HYcGlEPTB;MkKuNVU4PyEQvF2=	M1LwZ3NCVkeHUh?=
SF126	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTzPGE3UUN3ME2yNk4zPDZ7IN88US=>	MVfTRW5ITVJ?
HOP-92	NYX3bWRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTsSG5qUUN3ME2yNk4{OTZ5IN88US=>	MXXTRW5ITVJ?
CTB-1	M3jwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYH6Um9TUUN3ME2yNk41Pjd5IN88US=>	MVrTRW5ITVJ?
KYSE-270	NYDxdFBET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvkTWM2OD1{Mj65N\|U4KM7:TR?=	M4fsOHNCVkeHUh?=
SK-MEL-24	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHITWM2OD1{Mz6xPFch\|ryP	NYjhXGh{W0GQR1XS
Calu-3	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnqzTWM2OD1{Mz6yNVI5KM7:TR?=	MWfTRW5ITVJ?
GAMG	NH3pV2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\uTWM2OD1{Mz6yN\|Y4KM7:TR?=	M330cnNCVkeHUh?=
SW1573	NU[ydFVQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTJ\|Lke0NVUh\|ryP	MVXTRW5ITVJ?
MHH-NB-11	NWT4V49UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2r0OWlEPTB;MkSuNFE6PCEQvF2=	NYjX[WdWW0GQR1XS
TK10	NH;HN\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37nUWlEPTB;MkSuOVAyOyEQvF2=	NX7JOXFWW0GQR1XS
LB373-MEL-D	M3Kz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTJ2Lk[wOlQh\|ryP	MmOyV2FPT0WU
KALS-1	M2f5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDiTWM2OD1{ND63N\|I4KM7:TR?=	MYLTRW5ITVJ?
HUTU-80	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHSd3pKSzVyPUK1MlgxOzJizszN	M1vEbXNCVkeHUh?=
HuP-T3	M1zCNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETRXVVKSzVyPUK2MlE3PzRizszN	NXfxW2poW0GQR1XS
OE19	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml61TWM2OD1{Nj6yNVU{KM7:TR?=	NYDz[4kxW0GQR1XS
J82	MlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTJ4LkK0O\|Eh\|ryP	MkKwV2FPT0WU
DU-4475	M2HlcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zwc2lEPTB;Mk[uN\|gyQSEQvF2=	NYPQTnBQW0GQR1XS
DMS-53	NY\HNm1nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTJ4LkWxN\|gh\|ryP	Mn3hV2FPT0WU
COLO-741	NVzBfYpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LocmlEPTB;Mk[uPFM1PCEQvF2=	NYfDTJRYW0GQR1XS
SW48	M{HPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojITWM2OD1{Nj64PFIh\|ryP	MYTTRW5ITVJ?
IGR-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo[wTWM2OD1{Nj65N\|M1KM7:TR?=	M{LJTXNCVkeHUh?=
639-V	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTJ5LkCyOFUh\|ryP	M{\mVHNCVkeHUh?=
LK-2	NFHaUFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHX2O\|RKSzVyPUK3MlQyPDFizszN	MUjTRW5ITVJ?
NCI-H2347	MoH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnjN\|VUUUN3ME2yO{46Pjl7IN88US=>	M{nRPXNCVkeHUh?=
NCI-H2228	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm[3TWM2OD1{OD6wPVA2KM7:TR?=	Mo\zV2FPT0WU
LS-123	Mkf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVT0VFhCUUN3ME2yPE4yOjZ{IN88US=>	NYjCW5R7W0GQR1XS
U031	NF3CfIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HCfWlEPTB;MkiuNlUzKM7:TR?=	M2TNWnNCVkeHUh?=
NCI-H1792	M4DHTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrBTWM2OD1{OD60O\|IyKM7:TR?=	MXTTRW5ITVJ?
NCI-H2087	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPLTWM2OD1{OD63OVUzKM7:TR?=	MoO5V2FPT0WU
NCI-H2342	NF3p[\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTJ7LkWyNFgh\|ryP	MVrTRW5ITVJ?
SW626	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHrTWM2OD1{OT63OVYh\|ryP	NGO1WGxUSU6JRWK=
LB2518-MEL	NEHKV4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzUTWM2OD1{OT64NVUh\|ryP	MoWzV2FPT0WU
RXF393	M1njUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;0fGlEPTB;M{CuNFk2OiEQvF2=	NVfVZWE1W0GQR1XS
LC4-1	M1rFSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7WTWM2OD1\|MD6zNFkzKM7:TR?=	NIPneWhUSU6JRWK=
NCI-H1694	M4rOVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnNc4V1UUN3ME2zNE43PjJ2IN88US=>	M4rjfXNCVkeHUh?=
K5	Mom3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfNVYZKSzVyPUOwMlk4ODJizszN	MlXhV2FPT0WU
HDLM-2	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jIWmlEPTB;M{CuPVczPSEQvF2=	NXjuTnpoW0GQR1XS
BCPAP	NWn0W3pVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlG3TWM2OD1\|MT64N\|c6KM7:TR?=	MoP2V2FPT0WU
BC-3	MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nxPWlEPTB;M{KuNVQxOyEQvF2=	NID5cXdUSU6JRWK=
LB996-RCC	NFf0PW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkP5TWM2OD1\|Mj6yN\|U5KM7:TR?=	MkHSV2FPT0WU
NCI-H2009	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlm0TWM2OD1\|Mj60PVgyKM7:TR?=	MmjJV2FPT0WU
HTC-C3	MlLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjSTWM2OD1\|Mz63OVE6KM7:TR?=	MXXTRW5ITVJ?
LAMA-84	NF7mTHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmK0TWM2OD1\|ND60OFA4KM7:TR?=	MX3TRW5ITVJ?
CCRF-CEM	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvjTWM2OD1\|ND61O\|E2KM7:TR?=	NFjhcWdUSU6JRWK=
AN3-CA	MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXYfVZtUUN3ME2zOU4xPTZ6IN88US=>	MYjTRW5ITVJ?
NCI-H1734	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\Ub3BYUUN3ME2zOU4zPTZzIN88US=>	M{P4ZnNCVkeHUh?=
Ca-Ski	NFPY[WNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTN3LkSxNFEh\|ryP	MWnTRW5ITVJ?
U-266	NFHn[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvFTWM2OD1\|NT62NVE1KM7:TR?=	MmLSV2FPT0WU
SBC-5	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTIV2U6UUN3ME2zOU44PzhzIN88US=>	MX3TRW5ITVJ?
GT3TKB	Mo\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DWNWlEPTB;M{euNVE2KM7:TR?=	MnW0V2FPT0WU
MDA-MB-175-VII	MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDoTWM2OD1\|Nz6yNlQ5KM7:TR?=	NIrQNGVUSU6JRWK=
PFSK-1	NXLTbGp7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4SybGlEPTB;M{euNlQ{PSEQvF2=	NFzlSIRUSU6JRWK=
IMR-5	NXO2W3hpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;ZR20zUUN3ME2zO{4zPDh5IN88US=>	NEfobIxUSU6JRWK=
Daudi	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLSSZNkUUN3ME2zO{4{PTl5IN88US=>	MVnTRW5ITVJ?
A498	NH7tRmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DpNGlEPTB;M{euO\|IyQCEQvF2=	NXTN[GFbW0GQR1XS
SCC-4	M37XSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLNeWJ3UUN3ME2zO{44QDR\|IN88US=>	M2HoPHNCVkeHUh?=
COLO-680N	NIjhc29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jDdmlEPTB;M{iuNlg5PSEQvF2=	M3XneXNCVkeHUh?=
SK-MES-1	M{izTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfRSZJoUUN3ME2zPE4{OjF3IN88US=>	NIm1VJFUSU6JRWK=
SR	MmrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPFTWM2OD1\|OD61OFk2KM7:TR?=	NGLjclBUSU6JRWK=
LNCaP-Clone-FGC	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTN6LkW2N\|ch\|ryP	MYjTRW5ITVJ?
SK-HEP-1	M360R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{nDO2lEPTB;M{iuO\|gzOiEQvF2=	NWC2VoJKW0GQR1XS
BPH-1	M1njOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnzTWM2OD1\|OD64N\|I6KM7:TR?=	NYnqXYU5W0GQR1XS
NCI-H1755	NUHpT2JmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrkTWM2OD1\|OT61PFE4KM7:TR?=	MWTTRW5ITVJ?
LXF-289	NYS3NVN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTN7LkiwPFQh\|ryP	MX\TRW5ITVJ?
SW1088	NGnHSGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHSwUWJKSzVyPUSwMlIyODdizszN	Mo\DV2FPT0WU
MOLT-4	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7xfnJ3UUN3ME20NE4zQTBzIN88US=>	MVXTRW5ITVJ?
AsPC-1	M4PYTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7ld4lKSzVyPUSwMlQ2QDNizszN	NUXGN5ZpW0GQR1XS
HOP-62	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTRyLk[1Olgh\|ryP	M37Qb3NCVkeHUh?=
A172	M4DaNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3ITWM2OD12MD64OVEyKM7:TR?=	MVzTRW5ITVJ?
SN12C	NWrkcXBNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrnVo1bUUN3ME20NE46Ozh3IN88US=>	M3O2PXNCVkeHUh?=
MDA-MB-231	MmThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTRyLkm4PVgh\|ryP	NXXFWmxjW0GQR1XS
RPMI-2650	MlrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DmcmlEPTB;NEGuNVU6OyEQvF2=	MoTrV2FPT0WU
KYSE-140	NEL0Z3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\WN2lEPTB;NEGuPFEzOyEQvF2=	NVW4cYZmW0GQR1XS
KINGS-1	NETIW\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3PTWM2OD12Mj60Olk4KM7:TR?=	MUTTRW5ITVJ?
HSC-3	MnzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\tTWM2OD12Mj62OlYyKM7:TR?=	M2PUZnNCVkeHUh?=
PC-14	MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTR\|LkG4PFIh\|ryP	NFLqR5NUSU6JRWK=
COR-L105	MknjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\UV4RXUUN3ME20N{43PTB{IN88US=>	M{DZWHNCVkeHUh?=
BE-13	NX6zeWpIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\mOnpVUUN3ME20OE4zOzdzIN88US=>	NFvybFRUSU6JRWK=
NCI-H661	MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXS0PFdMUUN3ME20OE4zQTV6IN88US=>	MkO3V2FPT0WU
IST-MEL1	M1X2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTR2LkO1PVkh\|ryP	MVXTRW5ITVJ?
HCC1806	NVHhW4xNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\aSWlEPTB;NESuOVg4OyEQvF2=	MWTTRW5ITVJ?
COLO-800	NF2wSm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33xXWlEPTB;NESuPFQ2OyEQvF2=	NEm3bW9USU6JRWK=
IST-SL2	NX3QNFJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjIOJByUUN3ME20OU4yOjR5IN88US=>	NU\yUY9zW0GQR1XS
8305C	NHTGSW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;DWmlEPTB;NEWuN\|A6KM7:TR?=	NWnXbZFNW0GQR1XS
UACC-62	NVG0XWxqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rvW2lEPTB;NE[uNlg4PSEQvF2=	NWWyT2hoW0GQR1XS
COR-L23	M2XLVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILj[mNKSzVyPUS3MlE6QSEQvF2=	NHO1TolUSU6JRWK=
EFE-184	NVjGOYhMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rtbmlEPTB;NEeuN\|g5KM7:TR?=	MljJV2FPT0WU
DMS-114	Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTSPIV{UUN3ME20O{41OTR7IN88US=>	M4P1UnNCVkeHUh?=
KYSE-520	NIXZZnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPIPVV3UUN3ME20PE42OzF3IN88US=>	NXf3ZVJVW0GQR1XS
SNG-M	NXjpPWE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PJUWlEPTB;NEmuOFM1KM7:TR?=	NET1Z2lUSU6JRWK=
A2058	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTWTWM2OD12OT60PFg2KM7:TR?=	NYLUZo51W0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-EGFR / EGFR / p-IGF1R / IGF1R / p-IRS1 / IRS1 / p-ERK / ERK / p-AKT / AKT; PubMed: 26052929 Mol Carcinog Effects of linsitinib on EGFR and IGF1R Signaling Pathways. H1975, AR1, AR2 and AR3 cells were treated with control DMSO or linsitinib (2 and 5 μM) for 24 hours. Cell lysates were subjected to Western blot analysis. IGF1R-IRS-1-AKT phosphorylation was effectively inhibited by linsitinib in afatinib resistance cells whereas IRS-1-AKT phosphorylation was up-regulated by linsitinib in H1975 parental cells. p-IGF1R / IGF1R / p-mTOR / mTOR ; PubMed: 28440057 Cancer Med Linsitinib inhibits the activation of ERK and PI3K pathways. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, the phosphorylation of insulin‐like growth factor‐1 receptor (IGF‐1R), ERK1/2, and AKT/mTOR pathways were analyzed in TE‐13, TE‐1, and KYSE‐510 cell lines by western blot. cleaved caspase-3 / cleaved PARP; PubMed: 28440057 Cancer Med Reduced apoptosis in Linsitinib-resistant esophageal squamous cell carcinoma cells. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, cleaved PARP and activated Caspase‐3 were examined in TE-13, TE-1, and KYSE-510 cells by western blot. Tubulin was used as a loading control. pSrc(Y416) / Src; PubMed: 26515601 Oncotarget A549, H226Br, and H1975 cells were treated with 1 or 2 μM linsitinib (diluted in RPMI 1640 medium containing 10% FBS) for 12 or 24 h. Before harvest, cells were further stimulated with 10% FBS for 20 min. Cells were lysed with modified RIPA buffer and the protein expression was determined by Western blot analysis. p-STAT3(Y705) / STAT3 ; PubMed: 26041671 Mol Cancer H226B and H460 cells were subject to daily treatment with linsitinib (1 μM) for 1-5 days. pS6 / S6; PubMed: 21257723 Clin Cancer Res Western blot of NCI-H292 cells following 30 minutes of exposure to OSI-906 shows target inhibition of pIGF-1R and pIR at all doses as well as inhibition of downstream targets pAKT and pS6.	26052929 28440057 26515601 26041671 21257723
Immunofluorescence	FoxO1; PubMed: 27535223 J Biol Chem After starvation, control or βIRKO β-cell lines were treated with insulin (10 nm) in combination with high glucose (450 mg/dL), in the presence or absence of PI3K inhibitor LY294002, insulin receptor, and IGF1 receptor dual inhibitor OSI-906, Akt inhibitor MK2206, or MEK1/2 inhibitor U0126 for 30 min. A, representative pictures of β-cells immunostained for FoxO1 (red) and DAPI (blue). The scale bar indicates 20 μm.	27535223
Growth inhibition assay	Cell viability; PubMed: 26136493 Neuro Oncol InsR/IGF1R dual inhibitors, OSI-906 and BMS-754807, dose-dependently inhibited T4105 viability.	26136493

体内研究

OSI-906 作用于IGF-IR驱动的移植瘤鼠模型，抑制肿瘤生长，按 75 mg / kg剂量处理，导致100% TGI和 55% 衰退，按25 mg/kg剂量处理，导致 60% TGI，没有衰退。OSI-906处理犬，大鼠和小鼠，诱导不同的消除半衰期，消除半衰期分别为1.18 小时, 2.64小时和2.14小时。OSI-906按不同剂量单独处理给药雌性Sprague-Dawley 大鼠和雌性CD-1小鼠，每天一次，V_max值与OSI-906 剂量不成比例。OSI-906 按 25 mg/kg剂量处理12天，提高血糖值。OSI-906按75 mg/kg 剂量单独处理IGF-IR-驱动的人全长人类IGF-IR (LISN)移植鼠模型，在4 和24小时间最大程度抑制IGF-IR磷酸化(80%)，血浆药物浓度为26.6-4.77 μM。^[1] OSI-906 按60 mg/kg剂量单独作用于NCI-H292 移植鼠，处理2，4，24小时，抑制糖吸收。OSI-906 作用于NCI-H292移植鼠模型，抑制肿瘤生长。^[2]

激酶实验：^[1]	- 合并蛋白激酶生化实验: 通过以ELISA为基础的检测法(IGF-IR, IR, EGFR 和 KDR)或使用100 µM ATP的放射检测法进行蛋白激酶检测实验。在内部ELISA检测实验中，使用聚 (Glu:Tyr)作为底物，结合到96孔实验板表面，使用辣根过氧化物酶标记的自磷酸化抗体测定磷酸化。使用ABTS作为过氧化物酶底物，通过在405/490 nm处测量吸光度而测定结合的抗体。所有实验使用纯化的重组激酶催化域。在昆虫细胞中，人类IGF-IR或EGFR的重组酶表达作为NH2-末端谷胱甘肽S-转移酶融合蛋白，且在内部纯化。通过抑制百分数对log₁₀药品浓度的S型剂量-反应曲线测定IC50值。进行内部实验需重复进行实验，除非另有说明，取三次测量的最小值。
细胞实验：^[1]	- 合并 Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 和Hepa-1, RKO 3T3/hulGF-IR, H292 细胞 Concentrations: 0.02-0.8 μM Incubation Time: 3天 Method: 为了测定细胞增殖，细胞接种在含FCS 10%的合适培养基上，在不同浓度OSI-906存在时，温育3天。通过细胞内ATP含量的荧光量化，使用CellTiterGlo测定抑制细胞生长的情况。数据作为衡量最大增殖的一部分，通过在不同浓度 OSI-906存在时的细胞密度除以对照组（只用DMSO处理）细胞密度。 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: IGF-IR驱动的全长人类IGF-IR (LISN) 移植小鼠模型 Dosages: 25 mg/kg和75 mg/kg Administration: 口服处理，每天一次，持续14天 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	84 mg/mL (199.29 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5%DMSO+40%PEG300+5%Tween80+50%ddH2O	6.25mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Linsitinib (OSI-906) SDF

分子量	421.49
化学式	C₂₆H₂₃N₅O
CAS号	867160-71-2
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02546544	Completed	Drug: Linsitinib	Relapsed Ewing Sarcoma\|Refractory Ewing Sarcoma	University of Oxford\|European Organisation for Research and Treatment of Cancer - EORTC\|European Commission\|Astellas Pharma Inc\|Oxford University Hospitals NHS Trust	March 2014	Phase 2
NCT01672736	Terminated	Drug: ASP7487 Velcade Dexamethasone	Multiple Myeloma	University Health Network Toronto\|Multiple Myeloma Research Consortium\|Astellas Pharma Inc	September 2012	Phase 1\|Phase 2
NCT01529684	Completed	Drug: radio-labeled OSI-906\|Drug: OSI-906	Advanced Solid Tumors\|Pharmacokinetics of 14C-OSI-906	Astellas Pharma Global Development Inc.\|Astellas Pharma Inc	March 19 2012	Phase 1
NCT01221077	Completed	Drug: OSI-906\|Drug: Erlotinib\|Drug: Placebo	NSCLC\|Non Small Cell Lung Cancer	Astellas Pharma Inc	April 8 2011	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?
回答：
OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

泛IGF-1R抑制剂

GSK1904529A : Dual IGF-1R/IR inhibitor, IC50=27 nM/25 nM.
活性最高的IGF-1R抑制剂

BMS-754807 : IGF-1R, IC50=1.8 nM; InsR, IC50=1.7 nM.
用于临床的IGF-1R抑制剂

BMS-754807 : Phase II for Breast Cancer.
最新的IGF-1R抑制剂

PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.

研究领域

产品类型

定制您的化合物库

Linsitinib (OSI-906)

客户使用Selleck生产的Linsitinib (OSI-906)发表文献115篇：

产品安全说明书

IGF-1R抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Linsitinib (OSI-906) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-09-01)

技术支持

常见问题及建议解决方法

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

相关IGF-1R产品